When you invest, your capital is at risk.

by Stella Ong
Share

Immortal

We recently discussed how 3D printing can already produce organs (albeit not fit for human transplants yet). Interestingly, this is just one component of a whole domain of tech dedicated to extending human life: “immortality-as-a-service” or “IaaS”.

Estimated to reach a market value of US$64b by 2026, IaaS is yet to be accurately defined, currently falling between the healthcare and cloud industries. The term is also used in reference to both biological and digital immortality.

Biological immortality is pretty straightforward: scientists working on extending life through medical advancements, including 3D printing (as mentioned), gene therapy and nanotechnology. The field has generated a lot of investor interest in the recent years, leading to stand-alone companies like Unity Biotechnology ($UBX) and established tech companies like Google ($GOOGL) having enough funding to focus exclusively on the research. Studies have already gone far, with a certain biotech CEO setting an example. Bryan Johnson is 45 years old, but test results show that, biologically, he has a heart of a 37-year-old, skin of a 28-year-old and lungs of an 18-year-old. While impressive, his upkeep reportedly costs US$2m a year

Digital immortality is, comparatively, the cheap option. Instead of dropping two mill a year on advanced self-care, you may soon be able to “upload your personality” into a computer. This would allow you to transcend mortality in a way, and continue to digitally keep your loved ones company. Despite this raising plenty of questions on existentialism, the concept is popular among Metaverse companies and research is forging ahead.

Would you rather see advancements in biological or digital immortality – or do you think eternal life is overrated anyway?


Portrait photo of Stella Ong, Markets Analyst at Stake.

Stella Ong

Markets Analyst

Stella is a markets analyst and writer with almost a decade of investing experience. With a Masters in Accounting from the University of Sydney, she specialises in financial statement analysis and financial modelling. Previously, she worked as an equity analyst at Australian finance start-up, Simply Wall St, where she took charge of the market insights newsletter sent out to over a million subscribers. At Stake, Stella has been key to producing the weekly Wrap articles and social media content.


Related


Want more?

You know what to do

Insights, trends and company deep dives delivered straight to your inbox.


Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stake is the trading name of Hellostake Limited, a company registered in England and Wales (Company no. 11676409). Hellostake Limited is authorised and regulated by the UK Financial Conduct Authority under the Firm Reference Number 830771. Registered address: 85 Great Portland Street, London, W1W 7LT, United Kingdom.

When you invest, your capital is at risk.

The value of your investments can go down as well as up and you may receive back less than your original investment. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate independent taxation and legal advice. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services.

At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Please view ourTerms & Conditions,Privacy PolicyandDisclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance

Copyright © 2024 Stake. All rights reserved.